VERAXA Biotech (NASDAQ: VRXA) announced on July 2, 2026, the initiation of cell line development for its lead BiTAC(R) T-cell engager (BiTAC-TCE) program. The company is collaborating with ATUM, which will apply its Leap-In Transposase(R) technology to generate stable clonal cell lines to support IND/CTA-enabling activities and future clinical development.
The collaboration follows encouraging preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. It is intended to support CMC development, including early process, analytical and formulation development, as well as the production of material for nonclinical studies.
VERAXA’s BiTAC-TCE platform is designed to improve tumor selectivity by splitting the T-cell engager into two complementary precursors that activate only when both bind separate tumor targets on the same cell. The company believes this conditional “AND”-gated approach could reduce off-tumor toxicity associated with conventional T-cell engagers while maintaining anti-cancer activity, potentially enabling higher dosing and a broader therapeutic window.
This development marks a significant step forward for VERAXA’s pipeline. By advancing cell line development now, the company is laying the groundwork for manufacturing processes that will be critical for clinical trials and eventual commercialization. The partnership with ATUM, a leader in protein engineering and cell line development, leverages proven technology to accelerate timelines and improve yield and stability.
For investors, this news signals that VERAXA is moving its lead program from preclinical research into the development stage, reducing some of the early-stage risk. The company’s BiTAC platform has the potential to address a key limitation of existing T-cell engagers: off-tumor toxicity that narrows the therapeutic window. If successful, the BiTAC-TCE could offer a safer and potentially more effective option for patients with solid tumors.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution. The company is building a pipeline of bispecific T cell engagers, bispecific ADCs, and other innovative antibody-based therapeutics. BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
For more information, the full press release is available at https://ibn.fm/FCIlk. The latest news and updates relating to VRXA can be found in the company’s newsroom at https://ibn.fm/VRXA.
Forward-looking statements in this article involve risks and uncertainties as described in the company’s SEC filings. No undue reliance should be placed on these statements.
